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Oligosaccharide proﬁlingWe employed top- and middle-down analyses with multiple fragmentation techniques including electron
transfer dissociation (ETD), electron capture dissociation (ECD), and matrix-assisted laser desorption ionization
in-source decay (MALDI-ISD) for characterization of a reference monoclonal antibody (mAb) IgG1 and a fusion
IgG protein. Fourier transform ion cyclotron resonance (FT-ICR) or high performance liquid chromatography
electrospray ionization (HPLC-ESI) on an Orbitrap was employed. These experiments provided a comprehensive
viewon the protein species; especially for different glycosylation level in these two proteins, which showed good
agreement with oligosaccharide proﬁling. Top- andmiddle-downMS provided additional information regarding
glycosylation sites and different combinational protein species that were not available from oligosaccharide
mapping or conventional bottom-up analysis. Finally, incorporating a limited enzymatic digestion by immuno-
globulin G-degrading enzyme of Streptococcus pyogene (IdeS) with MALDI-ISD analysis enabled extended
sequence coverage of the internal region of protein without pre-fractionation.
Biological signiﬁcance: Oligosaccharide proﬁling together with top- and middle-down methods enabled:
1) detection of heterogeneous glycosylated protein species and sites in intact IgG1 and fusion proteins with
high mass accuracy, 2) estimation of relative abundance levels of protein species in the sample, 3) conﬁrmation
of the protein termini structural information, and 4) improved sequence coverage byMALDI-ISD analysis for the
internal regions of the proteins without sample pre-fractionation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Protein top-down analysis by mass spectrometry (MS) has provided
efﬁcient characterization of proteins in their intact forms including any
“protein species” [1–4]. According to Schlüter and Jungblut et al. [3], pro-
tein species are deﬁned as the different proteins derived from a single
gene. Post-translational modiﬁcations (PTM), nucleotide polymorphism,
and alternative splicing can generate a large number of different protein
species that derive from a single gene. Unlike protein isoforms, which
are genetically deﬁned, a protein species is chemically deﬁned and thus
includes also recombinant proteins such as monoclonal antibodies with
different PTMs. Top- and middle-down approaches could provide com-
plementary information to the bottom-up analysis of protein species be-
cause bottom-upanalysis alone, inwhichpeptides fromall of thedifferent
protein species of a protein are mixed, can lead to inconclusive detection
of some of the protein species present in amixture. Analysis of intact pro-
teins provides additional capabilities to identify PTMs such asoodlett),glycosylation that are commonly found in mAbs. Recently, incorporation
of tandemmass spectrometry (MS/MS) techniques like electron transfer
dissociation (ETD) and higher collisional energy dissociation (HCD) has
improved sequence coverage by top-down analysis [5,6]. Proteins can
also be studied further by limited or speciﬁc proteolysis to yield informa-
tion about protein isoforms andPTMsvia analysis of largepeptides or pro-
tein fragments, which has been referred to as middle-down analysis.
Antibodies represent a class of proteins that are key to mammalian
immunological defense systems. They bind to an antigen (protein, glyco-
protein, DNA, etc.) with a high degree of speciﬁcity thus neutralizing for-
eign biological material and xenobiotics. This process makes them
extremely valuable for use in diagnostics, general research, and as thera-
peutics. Since their introduction in the late 1980s, therapeutic mAbs have
become very popular drug candidates due to this high speciﬁcity and low
toxicity. At present, approximately 30 mAbs are used for human thera-
peutics for oncology, autoimmunity, inﬂammation, infectious diseases,
and metabolic disorders [7,8]. Most of the clinically approved mAbs are
IgG1s, which are composed of two heavy chains (50 kDa each) and two
light chains (25 kDa each) covalently linked by disulﬁde bridges.
Carboxyl-terminal domains (Fc domains) are conserved, but amino-
terminal domains (Fv domains) are variable in amino acid sequence,
94 B.Q. Tran et al. / Journal of Proteomics 134 (2016) 93–101resulting in variations in speciﬁcity. The structure of IgGs, with four high
molecular weight polypeptide chains held by inter- and intra-disulﬁde
bonds as well as non-covalent interactions make characterization of
mAbs by top down mass spectrometry very challenging.
As a complementary technique, middle-down analysis of the frag-
ments of mAbs produced by speciﬁc enzymes such as papain, pepsin
or immunoglobulin G-degrading enzyme of Streptococcus pyogenes
(IdeS) [9] can facilitate characterization. For instance, analyzing Fab
and F(ab’)2 fragments offer advantages over intact mAb analysis by re-
ducing nonspeciﬁc antigen binding to Fc region. On the other hand, the
Fc region can be used for in-depth glycosylation analysis.
As contribution to the special issue “Protein Species”, we sought to
study the sequence and PTM status of IgG molecules by top- and
middle-downMS. A protein species is deﬁned by chemical modiﬁcations
(i.e. sequence chain length and/or PTM) and includes recombinant pro-
teins such asmAbs produced as drugs [1–3]. As such, we employed oligo-
saccharideproﬁling analysis for comprehensive glycan identiﬁcation of an
IgG1mAb and a glycosylated IgG1 fusion protein. This was used as an or-
thogonal approach to top- andmiddle-down analyseswithmultiple frag-
mentation techniques including electron capture dissociation (ECD) [10],
electron transfer dissociation (ETD) [11], and MALDI-in-source decay
(ISD) [12]. All these fragmentation methods were employed on one of
two high-resolution MS instruments, a Fourier transform ion cyclotron
resonance (FT-ICR) MS [13,14] or an Orbitrap Elite MS. FT-ICR data were
further processed by application of a novel phase correction software,
Autophaser [15]. We determined heterogeneous combinations of glyco-
sylation on intact form of the proteins with high relevance to the glycan
proﬁling. Pyroglutamate modiﬁcation and lysine truncation were also
shown to occur respectively on N-terminus and C-terminus of the pro-
teins. In particular, we demonstrated the advantage of MALDI-ISD over
ESI (electrospray ionization) for analysis of a protein with high sialic
acid modiﬁcation, and for improved sequence coverage by a single
MALDI-ISD analysis of IdeS digest without sample pre-fractionation.
2. Material and methods
2.1. Protein samples
The recombinant human mAb (IgG1) and IgG1 fusion protein used
in this study were manufactured using standard cell culture, puriﬁca-
tion and formulation processes at MedImmune LLC. The mAb is a
novel IgG1 composed of two identical heavy and two identical light
chains, linked by disulﬁde bonds, with an approximate molecular
weight of 150 kDa. The IgG1 fusion protein is comprised of two identical
chains with a human protein domain fused onto the constant domain
(Fc) of a human IgG1 heavy chain. These two chains are covalently
linked by disulﬁde bonds at the IgG1 hinge, with an approximate mo-
lecular weight of 90 kDa. The mAb possesses a single N-glycosylation
site on each heavy chain within the CH2 domain (N297), while the fu-
sion protein has three N-glycosylation sites; one on the CH2 domain
of the IgG (N208) and two within the fusion protein (N76 and N108).
The mAb was expressed in stably transfected NS0 cells and puriﬁed
using a standard multi-step puriﬁcation process [16]. It is a fully human
monoclonal antibody (IgG1). The product quality of the mAb was con-
ﬁrmedby non-reducing gel electrophoresis (96.0% purity) andhighper-
formance size exclusion chromatography (99.7% purity). The fusion
protein was expressed in stably transfected Chinese hamster ovary
cells (CHO) and puriﬁed using a standard multi-step puriﬁcation pro-
cess [16]. The product quality of the IgG fusion protein was conﬁrmed
by non-reducing gel electrophoresis (99.0% purity) and high perfor-
mance size exclusion chromatography (99.8% purity).
2.2. Oligosaccharide proﬁling
Protein glycosylation was analyzed using a protocol modiﬁed from
Ahn et al. [17]. Brieﬂy, the protein was denatured in 2% w/v SDS, 1 Mß-Mercaptoethanol (product #63,689, Fluka, St. Louis, MO, USA) to en-
sure complete deglycosylation. The denatured fusion protein and the
native mAb were then incubated with PNGase F (New England Bio
Labs, Ipswich, MA) at 37 °C in 50 mM of Tris buffer pH 7.8 to remove
all N-linked oligosaccharides. The released oligosaccharideswere subse-
quently labeled at 37 °C for 60 min with a solution of 0.2 mM of 2-
aminobenzamine (2-AB), 0.2 mM of picoline borane (PICB), and 7.5%
formic acid (FA) in acetonitrile (ACN). The labeled glycans were
reconstituted in 100% ACN and then puriﬁed by solid phase extraction
to remove any large interfering molecules. The oligosaccharides were
diluted into 100%ACN, separated by AcquityUPLC using BEHAmide col-
umn (130Å, 1.7 μm,2.1mm×150mm). TheUPLC chromatographywas
performed using 50 mM of ammonium formate (buffer A) and 100%
ACN (buffer B) ﬂowing at 0.5 mL/min (60 °C). For themAb, a linear gra-
dient over 23 min from 27% A to 41% A was used to elute the oligosac-
charides, whilst a linear gradient from 28% A to 38% A over 45 min
was used for the fusion protein. Glycan peaks were detected by ﬂuores-
cence detection (Ex= 330, Em=420) and identiﬁed by retention time
with reference to previously characterized standards. Each peak was
quantiﬁed based on the individual peak area relative to the total peak
area detected. Peaks below the quantiﬁcation limit of the assay (2%)
were reported as ‘minor’ and those below the detection limit (0.1%)
were reported as ‘not detected’ (ND).
2.3. Sample preparation for mass spectrometry (MS) analysis
At ﬁrst, the samples were treated to remove impurities that were
present in the sample storage buffer prior to the mass spectrometry
analysis by off-line buffer exchange to 5% ACN and 0.1% TFA using
Amicon 100 kDaor 50 kDamolecularweight cutoff (MWCO) centrifugal
ﬁlters (product # UFC510024 and UFC505024, Merck Millipore,
Tullagreen, Carrigtwohill, Ireland) for the mAb and the fusion protein,
respectively. For the fusion protein that was in detergent-containing
buffer, additional detergent removal was applied to the sample by
Pierce detergent removal kit (product # 87778, Thermo Scientiﬁc, Rock-
ford, CA, USA) following the manufacturer's instruction. Puriﬁed intact
proteins were diluted in 50% acetonitrile and 0.1% formic acid at a
ﬁnal concentration of 12.5 μg/μL (mAb) and 10 μg/μL (fusion protein)
for the top-down MS analysis.
To reduce protein by breaking off disulﬁde bonds, the samples were
diluted to 1 μg/μL in 50mMof ammoniumbicarbonate buffer prior to di-
thiothreitol (DTT, product #43815, Sigma-Aldrich, St. Louis, MO, USA)
addition at ﬁnal concentration of 20 mM and incubated at 80 °C for
15 min. The reduced proteins were concentrated using Amicon 10 kDa
centrifugal ﬁlter (product # UFC201024, Merck Millipore). The fusion
proteinwas then subjected to the detergent removal using Pierce deter-
gent removal kit (Thermo scientiﬁc). The reduced proteins were diluted
in 50% ACN and 0.1% FA at a ﬁnal concentration of 17 μg/μL (mAb) and
7 μg/μL (fusion protein) for the top-downMS analysis. The reduced pro-
teins were also used for the MALDI-ISD application. The matrix 1,5-
diaminonaphthalene (1,5-DAN, product # 56451, Fluka, St. Louis, MO,
USA) in ACN was prepared fresh. One microliter reduced protein was
spotted ﬁrst and 1 μLmatrixwas added to the protein spot on a stainless
steel polished MALDI plate and then dried.
For the middle-down, proteins were digested by an enzyme, IdeS
(product # A0-FR1-020, Genovis AB, Lund, Sweden), according to
manufacturer's instruction. Brieﬂy, the proteins were diluted to 1 μg/
μL in 50 mM of ammonium bicarbonate solution. The IdeS was added
at a ratio of 1 unit per 1 μg of protein followed by 2 h of incubation at
37 °C. For the IgG1 mAb, additional ﬁltration was applied to separate
Fc and Fab fractions using a 50 kDa spin ﬁlter (Merck Millipore). To
further reduce the proteins, DTT was added to ﬁnal concentration of
20 mM to cleave disulﬁde bonds at 80 °C for 15 min. The reduced
samples were concentrated using 10 kDa ﬁlter (Merck Millipore). The
concentrated fusion protein was subjected to additional detergent re-
moval using Pierce detergent removal spin column (Thermo Scientiﬁc).
Table 1
Glycosylated protein species and relative abundance level detected by oligosaccharide
proﬁling of the IgG1 and the fusion protein. Glycans in bold are also detected by top-down
and middle-down analysis. Peaks below the quantiﬁcation limit of the ﬂuorescence
detection assay (2%) were reported as ‘Minor’ and peaks below 0.1% detection limit
were reported as ‘not detected’ (ND). Additional information regarding the glycan
nomenclature and structure is provided in Ref. [21], Fig. 5.
Glycan mAb Fusion
protein
Glycan mAb Fusion
protein
G0-GN Minor ND G2f + G N2% ND
G0f-GN N2% Minor G1f + NGNA Minor ND
G0 Minor N2% G2f + 2G Minor ND
G0f N30% N10% G2f + NGNA Minor ND
M5 Minor N2% G2f + G + NGNA Minor ND
G1f-GN Minor ND G1f + NANA ND N2%
G1 ND Minor G2f + NANA ND N10%
G1f N25% N2% G2f + 2NANA ND N10%
M6 Minor ND G3f + NANA ND N2%
G1f-GN + G Minor ND G3f + 2NANA ND N2%
G2f N5% N2% G3f + 3NANA ND N2%
G1f-GN + NGNA Minor ND
Fig. 1. Sample preparation and data acquisition workﬂow for (A) top-down andmiddle-down analyses of the IgG1mAb and the fusion protein, (B) IdeS digestion of the mAb produces Fc
and F(ab’) domainswhich are further cleaved to Fc/2, LC and Fd’ byDTT treatment, and (C) IdeS digestion of the fusion protein cleaves right below the hinge region and further releases N-
terminal and C-terminal Fc domains by DTT treatment.
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0.1% TFA. Approximately 7 μg/μL of the ﬁnal sample concentration was
used for the middle-down MS analysis.
2.4. MS data acquisition and data processing
Accurate mass measurement of the intact protein was acquired as
follows. The puriﬁed intact protein was ionized by electrospray and in-
troduced to 12 Tesla FT-ICR mass spectrometer (Solarix XR, Bruker,
Bremen, Germany) at a ﬂow rate of 2 μL/min. Accurate mass spectrum
was recorded inmagnitudemode inm/z range of 400–4000 at transient
data of 128 k words with an accumulation of 1700 scans for the fusion
protein and 2000 scans for themAb. Continuous accumulation of select-
ed ions (CASI) [18], a gas-phase ion enrichment technique, was applied
to enhance the peak cluster signal at different charge states. CASI iso-
lates ions of a narrowm/zwindow and stores them in an ion trap for re-
petitive cycles of laser ablation prior to sending the enriched ion
population to the ICR cell for detection. The technique increases the dy-
namic range for peak detection. For an example, CASI in range of 2340–
2380 m/z for charge state 63+ of the intact mAb was acquired. The re-
duced and IdeS treated fusion protein was also measured in CASI for
charge state 17+. FT-ICR data was processed using DataAnalysis soft-
ware version 4.2 (Bruker). Mass and charge state of the protein species
were manually calculated with Charge State Ruler function.
ETD of the reduced proteins was carried out by isolating a single
charge state in collision cell while ECDwas performed for several selected
charge states in ICR cell. ETD reagent accumulation time, ion accumula-
tion time and reaction time were tuned for optimal fragment ion signal.
For the MALDI-ISD FT-ICR, in-source decay (ISD) spectrum was ac-
quired with a transient of 1 mega (M)-word data points, over a 400–
10,000 m/z with estimated resolving power of 270,000 at m/z 400.
Quadrupole ﬁltrationwas set at 1000 or 2000. Magnitudemode spectra
of MALDI-ISD experiments were subjected to Hanning algorithm based
baseline and phase correction using Autophaser [15]. Sophisticatednumerical annotation procedure (SNAP) algorithm [19] was applied to
the phased MALDI-ISD spectrum as well as ETD and ECD spectra
extracting isotopic fragment ions at a quality factor threshold of 0.5
and signal-to-noise of 0.5, and relative intensity threshold (base peak)
of 0.01%. The phased spectrum was post-acquisition calibrated using
the observed c-ions as internal calibrants. c-, z- and z + 2 ions were
identiﬁed by matching the observed masses with theoretical ones
using Biotools version 3.2 (Bruker) and Sequence Editor 3.2 (Bruker)
at a MS/MSmass tolerance of 50 ppm. G0f and G1f glycosylation of ser-
ine site 300, protein N-terminal modiﬁcations were deﬁned as optional
modiﬁcations.
The IdeS treated and reduced mAb was also subject for the LC ETD
MS/MS acquisition on Orbitrap Elite (Thermo Fisher Scientiﬁc, Saint
Jose, CA, USA). Approximately14 μg protein sample containing the Fc
Fig. 2.A.Mass spectrum of the 63+ charge state of IgG1mAb generated by continuous accumulation of selected ion (CASI)mass spectrometry atm/z 2360. Themass spectrumwas result
from accumulation of 2000 scans collected in a time domain of 128 K word data points. The peaks demonstrate heterogeneous glycosylation of protein species in combination with C-
terminal lysine truncation and N-terminal glutamine (Q) to pyroglutamate (pyroGlu) conversion on the heavy chain. Bold font indicates the glycoforms identiﬁed by both intact protein
analysis and oligosaccharide proﬁling analysis. B.MALDI-ISDmass spectrum of theDTT/IdeS treated IgG1mAb. (a) light chain, (b) Fd, and (c) Fc/2 regions. Amino acid residues underlined
were detected by c or z+2 ions after phase correctionwithmass error threshold of 50 ppm, covering 33.8% of the light chain, 24.8% Fd, and 22.6% Fc/2. N-terminal pyroglutamate (pyroGlu,
pE) residue and C-terminal lysine truncation were detected on the heavy chain.
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Table 2
Glycosylatedprotein species detected by accuratemassmeasurement of the IgG1mAbby top- andmiddle-downanalysis of 63+charge state. Bold font indicates the glycoforms identiﬁed
by both intact protein analysis and oligosaccharide proﬁling analysis. The abundance level of the glycoformswas in good agreement by the twomethods. Additional information regarding
the glycan nomenclature and structure is provided in Ref. [21], Fig. 5.
Glycoforms Peak z Observed mass Theoretical mass Mass error (Da) Mass error (ppm)
G0f/G0f-GN 2347.51957 63+ 147,830.27476 147,831.977282 −1.70 −11.5
G0f/G0f 2350.79054 63+ 148,036.34576 148,035.056655 1.29 8.7
G0f/G1f;
G0f/M6
2353.34094 63+ 148,197.0266 148,197.109478 −0.08 −0.5
G0f/G2f;
G1f/G1f
2355.89687 63+ 148,358.04457 148,359.162301 −1.11 −7.5
G0f/G2f + G;
G1f/G2f
2358.51070 63+ 148,522.71564 148,521.215124 1.50 10.1
G0f/G2f + 2G;
G1f/G2f +G;
G2f/G2f
2361.07788 63+ 148,684.44818 148,683.267947 1.18 7.9
G1f/G2f + 2G;
G2f/G2f + G
2363.65066 63+ 148,846.53319 148,845.32077 1.21 8.1
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Jupiter 5 μm C5 particles (product # 04A-4052, Phenomenex, Torrance,
CA, USA). The protein fragments were eluted by a fast gradient of ACN
from 5% to 50% in 15 min at a ﬂow rate of 0.3 μL/min. The fragments
were scanned in range of 350–3500 m/z at resolving power ofFig. 3. Amino acid sequence coverage for (A) IgG1mAb light chain and (B) heavy chain determi
coveragewas 35.9% and52.6% for theheavy and light chains, respectively. Glutamine (Q) to pyro
heavy chain. One glycosylation site is highlighted in yellow.120,000. Most intense peaks were separated and selected for ETD frag-
mentation. ETD reaction timewas optimized for an individual precursor
peak. ETD spectrumwas acquiredwith 5microscans at resolving power
of 120,000 and the averaged scanwas used for the sequencing byMASH
Suite version 1.0 [20].ned by a combination ofMALDI-ISD andmiddle-down ETD analyses. The overall sequence
glutamate (pyroGlu, pE) conversion and C-terminal lysine truncationwere detected on the
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3.1. Analysis of the IgG1 mAb
The various sample preparation workﬂows for MS based analyses of
the IgG1 are provided in Fig. 1A. The IgG1was analyzed in various forms
including intact, reduced, and as IdeS produced fragments. These were
subjected to high mass accuracy measurements of protein species.
Oligosaccharide proﬁling by enzymatic release of glycans and HPLCFig. 4. A. Mass spectrum of the 17+ charge state of fusion protein generated by continuous a
was result from accumulation of 200 scans collected in a time domain of 1 M word data poin
heterogeneous combination of glycosylation with low levels of sialylation. B. MALDI-ISD mass
matched to sequences of (a) N-terminal and (b) C-terminal fragment. Annotated fragment ionseparation provided a comprehensive glycan list (Table 1, see Figure 5
in ref. [21]). This approach, however, requiredmultiple sample prepara-
tion steps that include enzymatic glycan cleavage by PNGase F and oli-
gosaccharide labeling. Additionally, it could not resolve a combination
of glycans present in different protein species, such as the glycosylation
status of all polypeptide chains on an intactmAb. On the other hand, in-
tact protein top-down analysis by ESI FT-ICR CASI at charge state 63+
successfully identiﬁedmultiple glycoformson the IgG1 (Fig. 2A). The ac-
curatemassmeasurement enabled not only the determination of glycanccumulation of selected ion (CASI) mass spectrometry at m/z 1500. The mass spectrum
ts with an estimated resolving power of 270,000 at m/z 400. Major peaks demonstrate
spectra of the DTT/IdeS-treated fusion protein. The phase corrected mass spectrum was
s, c and z+2, span 33.6% and 41.4% of N-terminal and C-terminal sequences, respectively.
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shown by the seven abundant peaks. The detected glycoforms demon-
strated heterogeneous heavy chain glycosylation as detailed in
Table 2. The seven detected glycoforms represented themost abundant
seven out of the 17 glycans determined by oligosaccharide proﬁling
(Table 1). And the abundance levels of the identiﬁed glycoforms were
in good qualitative agreement between the two analyses, in which the
combination of G0f and G1f represented the most abundant glycoform
observed.
Modiﬁcations on termini, such as C-terminal lysine truncation and/
or N-terminal glutamine (Q) to pyroglutamate (pyroGlu) conversion,
are other PTMs that could occur on mAbs during production or storage
process [22,23]. The seven most abundant protein species of the IgG1
were determined to contain N-terminal pyroGlu conversion and C-
terminal lysine truncation on the heavy chain at average mass error
0.3 Da (2.1 ppm).
Analyses of the reduced IgG1 using the ESI FT-ICR and LC–MS on OT-
Elite was performed to determine if the different glycoforms can be de-
tected and the termini modiﬁcation can be conﬁrmed. The observed ac-
curate masses of the heavy chains indicated predominant glycosylation
of G0f, G1f and G2f as well as the truncation of C-terminal lysine and N-
terminal pyroGlu conversion (data not shown). The results were in
good agreement with the intact analysis of the IgG1.
MALDI-ISD has been developed and used as an alternate to N-
terminal Edman sequencing for protein characterization [12]. The
advantage of MALDI-ISD is the rapid sequencing capability of both N-
and C-terminal for greater than 50 amino acid residues without the
need for protein hydrolysis. In comparison, Edman sequencing is limit-
ed toN-terminal sequences of polypeptides shorter than 50 residues (in
practice, under 30) due to the efﬁciency of release of the amino acid de-
rivative [24]. We employed 1,5-DAN as MALDI matrix in our experi-
ments since it was reported to be one of the most efﬁcient matrices
for MALDI-ISD to generate c- and z + 2 ion series [25,26]. To improve
fragmentation efﬁciency for better sequence coverage, the IgG1 was in-
cubated with DTT to break disulﬁde bonds producing heavy and light
chains prior to MALDI-ISD analysis, but these were not separated prior
toMS analysis. Thephase correctedMALDI-ISDmass spectrumof the re-
duced IgG1 (see Figure 1 in Ref. [21]) was searched against a light chainFig. 5. Fusion protein sequence coverage was determined by combination of MALDI-ISD and m
truncation and three glycosylation sites are highlighted (green-located on Fc; yellow-located oor heavy chain sequence database with the optional C-terminal lysine
truncation andN-terminal pyroGlu conversion. The notable observation
was the detection of up to 70 N-terminal residues and 47 C-terminal
residues for the light chain whereas the heavy chain sequence was de-
tected by slightly fewer residues. Phase correction of the MALDI-ISD
spectrum by Autophaser software improved the resolving power and
mass accuracy of the peaks, but showed no signiﬁcant improvement
in detected sequence coverage.
Given the typical 400–10,000 m/z range that MALDI-ISD covers,
obtaining a complete sequence of the heavy (349 aa) and light chains
(213 aa) was quite challenging especially for the internal sequence
regions. This challenge prompted the use of the immunoglobulin
degrading enzyme from Streptococcus pyogenes, IdeS [9], which cleaves
Glycine–Glycine (G–G) located underneath the IgG1 hinge region to
further fragment the heavy chain into the Fc/2 and Fd prior to MALDI-
ISD analysis (Fig. 1B). The MALDI-ISD of IdeS treated sample produced
more product ions from simultaneous fragmentation of the Fc/2 and
Fd regions and resulted in improved sequence coverage for the heavy
chain (Fig. 2B). The overall sequence coverage by MALDI-ISD was
37.6% and 23.6% for the light and heavy chains, respectively. MALDI-
ISD has been previously applied to top-down PTM studies for O-
glycosylation andother glycoproteins [26,27]. Similar to the observation
made by Chaurand et al. [28], we noted that the detection of the c-ions
of mAb Fd domain in the MALDI-ISD mass spectrum stopped at Y299,
which is right before NST motif of N-glycosylation (Fig. 2B). This obser-
vation suggests that the peptide bond fragmentation could be ham-
pered in the presence of the carbohydrate group.
In recent reports, IdeS treated protein fragments were LC separated
to produce light chain, Fd and Fc/2 prior to either ETD analysis or
MALDI-ISD using super DHB matrix [9,29]. LC-ETD analysis of
Adalimumab resulted in sequence coverage of 50% for Fc/2 and light
chain, and 30% for Fd domains [9]. LC-MALDI-ISD of off-line pre-
fractionated centuximab produced 61.5% light chain coverage while
no information regarding heavy chain coverage was provided [29]. In
the current study, MALDI-ISD analysis of IdeS treated mAb fragments
of approximately 25 kDa allowed sequence up to 37.6% for the light
chain, 22.6% for Fd and 24.8% for Fc/2 in a single analysis without need
for pre-fractionation or combing a multiple off-line LC fractions.iddle-down ETD analysis with an overall sequence coverage of 61.0%. C-terminal lysine
n non-Fc).
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by rapid nano-LC gradient coupled to an OT-Elite. The precursor ions of
each fraction, including the light chain, Fc/2, and Fd, were isolated and
subject to ETD fragmentation generating c- and z- ions. Analysis of the
ETD tandem mass spectra resulted in detection of fragment ions that
cover the central regions, 92–122 for the light chain and 98–138 for
the Fd fragment (see Figure 3A and 3B in ref. [21]). These central regions
were previously not accessible by MALDI-ISD analysis of the reduced
sample. Additionally, N-terminal glutamine to pyroGlu conversion of
the heavy chain as previously determined by the intact protein analysis
was conﬁrmed with 3.9 ppm error (0.1 Da) from ETD analysis of the Fd
domain (see Figure 3B in Ref. [21]).
While the top-down analysis of the intact or reduced protein provid-
ed accurate and rapid determination of different glycosylation protein
species of themAb, themiddle-down analysis by IdeS proteolysis great-
ly enhanced the sequence coverage by providing more efﬁcient frag-
mentation capability. Seven highly abundant glycosylated protein
species were determined which were all modiﬁed with N-terminal
pyroGlu conversion and C-terminal lysine truncation of the heavy
chain. The MALDI-ISD showed a superior performance for sequencing
over ECD and ETD analysis in the FT-ICR (data not shown). The
middle-down analysis following IdeS by LC–MS/MS ETD greatly en-
hanced sequencing of the central regions of the mAb. By employing
multiple fragmentation techniques, a sequence coverage of 35.9% and
52.6% for heavy and light chains, respectively, was obtained (Fig. 3). Dif-
ﬁculty in accessing the internal region of the sequence might relate to
reformation of disulﬁde bonds that would prevent effective fragmenta-
tion of the protein, especially from ESI generated ions. However, even
with alkylation of cysteine and use of other denaturing chemicals,
such as guanidine hydrochloride we did not see improvement in se-
quence coverage (data not shown). Both the size and structural confor-
mation of the studied IgG1 could be a contributing factor as well.
Considering a recent study that reported 100% sequence coverage of
mAb by analyzing peptide fragments as small as 3.4 kDa on average
by extended bottom-up approach [30], the sequence coverage observed
in this study from analyzing 25 kDa fragment was reasonable.
3.2. Analysis of the IgG fusion protein
The pattern of glycosylation in an IgG1with a single N-glycosylation
site in the Fc is less complex than that observed on proteinswith non-Fc
glycosylation sites. In order to test the analytical approach on a protein
with non-Fc glycosylation, we analyzed the sequence of an IgG fusion
protein. The fusion protein is a dimer comprised of six total N-
glycosylation sites (one Fc and two non-Fc sites within the fusion pro-
tein per chain) with a heterogeneous range of glycan structures as
shown by the oligosaccharidemapping analysis (Table 1). These include
bi- and tri-antennary sialylated species not normally seen on Fc glycans
and likely arising from the two glycosylation siteswithin the fusion pro-
tein. Intact protein analysis by FT-ICR supported the oligosaccharide
data, detecting a complex combination of glycosylated protein species
by use of only accurate mass measurement (see Figure 4 in Ref. [21]).
These glycoforms were predominantly sialic acid modiﬁcations deter-
mined by mass difference of 37 on protein species at charge state
38+ of the fusion protein. Themost abundant protein species observed
had the combination of (G1f)1, (G0f)1, (G2fS1)2, and (G2fS2)2 with C-
terminal lysine truncation, which was determined with a mass error
of 1.6 Da (18 ppm). Due to the large number of heterogeneous
glycoforms in the intact sample, which hampered accurate detection
of each glycoform, consecutive analysis was done by use of CASI FT-
ICR after DTT reduction and/or on a DTT/IdeS treated sample. Use of
IdeS cut the reduced fusion protein into two large peptides of approxi-
mate 45 kDa each, resulting in one N-terminal domain fragment and a
C-terminal Fc fragment (Fig. 1C). By analyzing the C-terminal fragment,
seven glycoforms in which G0f and G1f were the most high abundant
were observed (Fig. 4A). The detailed mass measurement and errorinformation of these glycoforms can be found in Ref. [21], Table 1. This
data was in agreement for the number of glycans detected by oligosac-
charide proﬁling (in Table 1) and demonstrates the ability of middle-
down MS to determine the site, as well as the nature, of glycosylation
on a protein.
The N-terminal fragment of the fusion protein has two N-
glycosylation sites per chain, however ESI analysis by FT-ICR or OT-
Elite could not detect the presence of the N-terminal fragment suggest-
ingpoor ionization due to the structural conformation, high level of neg-
ative charge sialic acid residues or stoichiometric properties of the N-
terminal fragment. The large number of heterogeneous glycosylation
might also contribute to the poor signal with low detection limit.
MALDI-ISDwas employed to analyze theDTT reduced fusion protein
with andwithout IdeS treatment. Similar to the IgG1 analysis, the phase
corrected MALDI-ISD of the DTT reduced fusion protein conﬁrmed the
C-terminal lysine truncation and provided fragment ions that covered
approximately 65 residues from both termini with a total of 25.3% se-
quence coverage leaving the most of the internal region not sequenced
(see Figure 6 in ref. [21]).When IdeS digestionwas added, the sequence
coverage of the fusion protein increased to 38.2% (Fig. 4B). Notably, both
the N- and C-terminal fragments of the fusion protein were detected by
MALDI-ISD suggesting an advantage of this technique over ESI for anal-
ysis of fusion proteins with complex heterogeneous glycosylation sites.
Similar to the observation made on the mAb analysis, ISD fragmen-
tation stopped right before the NST motif, at Y206, for the C-terminal
fragment of the fusion protein. However, the NGT motif on the N-
terminal fragment was observed by the z+2 ions suggesting that the
NGT motif may have lost a glycan group during ISD fragmentation
(Fig. 4B).
The DTT/IdeS treated sample was also subjected to LC-MS analysis
on the Orbitrap Elite. Similar to the FT-ICR ESI analysis, only the C-
terminal glycoforms were detected whereas none of the N-terminal
peakswere present. Ionization efﬁciency of the N-terminal might be se-
verely limited in both FT and OT instruments by the ESI. ETDmass spec-
tra of the two most abundant peaks provided 47.6% sequence coverage
for the C-terminal fragment and conﬁrmed the G0f and G1f glycosyla-
tion via detection of glycan-containing fragment ions (see Figure 8 in
Ref. [21]).
By use of the multiple fragmentation technique including MALDI-
ISD and ETD, overall 61.0% sequence coverage was achieved (Fig. 5).
The sequence analysis byMASH Suite indicated that the protein is trun-
cated at K357, the C-terminus sequence. Comprehensive glycoforms
were detected by intact protein analysis with less than 2 Da error in
mass accuracy, which provided accurate identiﬁcation of glycans, G0f,
G1f and G0 (Fig. 4A). The abundance level of the each glycans was con-
ﬁrmed by analysis from ETD fragmentation. Finally, middle-down anal-
ysis of the DTT/IdeS treated sample provided detection of more than
seven potential glycoforms with mass error less than 2.4 Da that was
in good agreement with the oligosaccharide proﬁling data.
4. Conclusions
Top- and middle-down analyses, either used alone or in combina-
tion, together with multiple ion dissociation techniques proved in com-
posite to be powerful tools for structural characterization of proteins
circumventing what have otherwise been onerous sample preparation
requirements. The top-down analysis by 12T FT-ICR and an Orbitrap
provided superior performance in 1) detection of heterogeneous
glycosylated protein species of intact proteins at high mass accuracy,
2) estimation of relative abundance levels of protein species, and 3) con-
ﬁrmation of the protein structural information (i.e. C-terminal K trunca-
tion and/or N-terminal modiﬁcation). Middle-down analysis of the IdeS
hydrolyzed protein fragments, particularly in combinationwithMALDI-
ISD, enabled the conﬁrmation of the N-terminal Glutamine to
Pyroglutamate conversion for the mAb and C-terminal truncations in
both mAb and the fusion proteins. It also enhanced sequencing of the
101B.Q. Tran et al. / Journal of Proteomics 134 (2016) 93–101central region of the proteins resulting in improved sequence coverage.
While MALDI-ISD showed limited performance determining N-
glycosylation sites, use of MALDI in addition to ESI was critical in char-
acterization of large proteins. This was due in part to the difﬁculty of
keeping the two large protein fragments from reforming disulﬁde
bonds that in turn affect structural conformation and ionization efﬁcien-
cy. Oligosaccharide mapping together with top- and middle-down
methods enabled comprehensive glycan proﬁling and detection of the
multiple glycosylation protein species in the proteins studied.
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